Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection

A method of identifying a binding partner for an FPR class receptor that inhibits HIV infection comprising the steps of:

• providing a cell having a CCR5 receptor and a FPR class receptor;
• contacting said cell with a candidate binding partner;
• and
• identifying the candidate binding partner as a binding partner if the candidate binding partner binds to an FPR class receptor and induces the phosphorylation of CCR5.

A method of identifying a binding partner for an FPR class receptor that inhibits HIV infection comprising the steps of:

• providing a cell having a CCR5 receptor and a FPR class receptor;
• contacting said cell with a candidate binding partner;
• and
• identifying the candidate binding partner as a binding partner if the candidate binding partner binds to an FPR class receptor and induces the downregulation of the CCR5 receptor at the cell surface.

A method of identifying a binding partner for an FPR class receptor that inhibits HIV infection comprising the steps of:

• providing a cell having a CCR5 receptor and a FPR class receptor;
• contacting said cell with a candidate binding partner;
• and
• identifying the candidate binding partner as a binding partner if the candidate binding partner binds to an FPR class receptor and inhibits HIV fusion.

A method of identifying a V3 peptide-like adjuvant comprising the steps of:

• providing a cell having a FPR class receptor;
• contacting said cell with a candidate V3 peptide-like adjuvant;
• and
• identifying the candidate V3 peptide-like adjuvant as a V3 peptide-like adjuvant if the candidate V3 peptide-like adjuvant activates the FPR class receptor.

A method of identifying a W peptide-like adjuvant comprising the steps of:

• providing a cell having a FPR class receptor;
• contacting said cell with a candidate W peptide-like adjuvant;
• and
• identifying the candidate W peptide-like adjuvant as a W peptide-like adjuvant if the candidate W peptide-like adjuvant activates the FPR class receptor.

A method of identifying a V3 peptide-like immunosuppressant comprising the steps of:

• providing a cell having a FPR class receptor;
• contacting said cell with a candidate V3 peptide-like immunosuppressant;
• and
• identifying the candidate V3 peptide-like immunosuppressant as a V3 peptide-like immunosuppressant if the candidate V3 peptide-like immunosuppressant inhibits the activation of the FPR class receptor.

A method of identifying a W peptide-like immunosuppressant comprising the steps of:

• providing a cell having a FPR class receptor;
• contacting said cell with a candidate W peptide-like immunosuppressant;
• and
• identifying the candidate W peptide-like immunosuppressant as a W peptide-like immunosuppressant if the candidate W peptide-like immunosuppressant inhibits the activation of the FPR class receptor.

A method of making a pharmaceutical product that inhibits HIV infection comprising:

• providing a binding partner;
• providing a cell having an FPR class receptor and a CCR5 receptor;
• contacting the cell with the binding partner under conditions that allow the binding partner to interact with theFPR class receptor on the cell;
• identifying the presence or absence of phosphorylation of the CCR5 receptor;
• and
• incorporating the binding partner into the pharmaceutical product upon observation of the presence of phosphorylated CCR5.

A method of making a pharmaceutical product that inhibits HIV infection comprising:

• providing a binding partner;
• providing a cell having an FPR class receptor and a CCR5 receptor;
• contacting the cell with the binding partner under conditions that allow the binding partner to interact with theFPR class receptor on the cell;
• identifying the presence or absence of the CCR5 receptor at the cell surface;
• and
• incorporating the binding partner into the pharmaceutical product upon observation of the absence of CCR5 at the cell surface.

A method of making a pharmaceutical product that inhibits HIV infection comprising:

• providing a binding partner;
• providing a cell having an FPR class receptor and a CCR5 receptor;
• contacting the cell with the binding partner under conditions that allow the binding partner to interact with theFPR class receptor on the cell;
• identifying the presence or absence of HIV infection;
• and
• incorporating the binding partner into the pharmaceutical product upon observation of the absence of HIV infection.